Our results show the efficacy of CSF-1R inhibition for the blockade of GAMM proliferation and that the combination of 18F-FET and 18F-DPA-714 PET can be used to monitor CSF-1R therapy–induced changes in the glioma microenvironment. Here, CSF1R is linked to central nervous system cancer.